Midodrine: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Caesar Schinas
m (Bot: Replacing medical templates with CZMed)
Line 44: Line 44:


== External Links ==
== External Links ==
* {{DailyMed}}
{{CZMed}}
* {{MedMaster}}
* {{DrugBank}}

Revision as of 00:24, 3 June 2009

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
(CC) Image: David E. Volk
Midodrine.

Midodrine, or midodrina or midodrinum, is an ethanolamine derivative that is an alpha-1 adrenergic receptor agonist used as a vasoconstrictor agent in the treatment of hypotension (low blood pressure). Its chemical IUPAC name is 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide, and its chemical formula is C12H18N2O4. It is sold under the brand name ProAmatine®. One of its major metabolites, desglymidodrine, formed by the desglycination of midodrine, is an alpha1-agonist and is the active substance associated with this drug.

In patients with orthostatic hypotension, it raises the systolic and diastolic blood pressure in standing, sitting and supine positions. Activation of the alpha-1 adrenergic receptors in the arteriolar and venous vasculature increases vascular tone and elevates the blood pressure. It does not stimulate cardiac beta-adrenergic receptors.

Adverse effects

Symptoms of overdose include hypertension, goosebumps, urinary retention and a sensation of coldness.

Drug interactions

Although increased arterial pressure occurs when this drug is used in combination with many other drugs, possible hypertensive crisis can occur when taken with tranylcypromine, rasagiline, phenelzine and isocarboxazid. Less dangerous increases in arterial pressure may occur when taken in combination with:

External Links

The most up-to-date information about Midodrine and other drugs can be found at the following sites.